Phio Pharmaceuticals Terminates Share Purchase Agreement With Triton Funds
Phio Pharmaceuticals Terminates Share Purchase Agreement With Triton Funds
Marlborough, Massachusetts–(Newsfile Corp. – July 5, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it has terminated its share purchase agreement with Triton Funds LP, which afforded Triton the opportunity to purchase up to 18.8% of the Company's common stock.
馬爾伯勒，馬薩諸塞州-（新聞稿發佈 corp. - 2024年7月5日）-Phio Pharmaceuticals corp.（納斯達克股票代碼：PHIO），一家臨床階段的生物技術公司，其專有的INTASYL siRNA基因沉默技術旨在使免疫細胞更有效地殺滅腫瘤細胞，今天宣佈已終止其與Triton Funds LP的股份購買協議，該協議爲Triton提供了購買公司普通股的機會，最高可買入18.8％。
About Phio Pharmaceuticals Corp.
關於Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
Phio Pharmaceuticals Corp. (納斯達克:PHIO)是一家臨床階段的生物技術公司，其專有INTASYL siRNA基因沉默技術旨在使免疫細胞在殺死腫瘤細胞方面更加有效。INTASYL是唯一專注於免疫學腫瘤治療領域的自釋放RNAi技術。INTASYL藥物精確地針對特定蛋白質，降低了身體對癌症的抵抗能力，而不需要專門的配方或藥物輸送系統。
For additional information, visit the Company's website, .
有關更多信息，請訪問公司網站。
Contact:
Phio Pharmaceuticals Corp.
ir@phiopharma.com
聯繫方式：
Phio Pharmaceuticals Corp.
ir@phiopharma.com
PR Contact
Michael Adams
Bridge View Media
adams@bridgeviewmedia.com
PR聯繫人
邁克爾·亞當斯
Bridge View Media
adams@bridgeviewmedia.com
To view the source version of this press release, please visit
要查看此新聞發佈的源版本，請訪問